Do Visible Residue Limits Make the 10-ppm Carryover Limit Obsolete? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Do Visible Residue Limits Make the 10-ppm Carryover Limit Obsolete?
The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 60-63

References

1. K.M. Jenkins and A.J. Vanderwielen, Pharm. Technol., 18 (4), 60–73 (1994).

2. R. J. Forsyth and D. Haynes, Pharm. Technol., 22 (9), 104– 112 (1998).

3. D. A. LeBlanc, D. D. Danforth, and J. M. Smith, Pharm. Technol., 17 (10), 118–1124 (1993).

4. B. D. Naumann and P. A. Weideman, Human Ecol. Risk Assess. 1 (5), 590–613 (1995).

5. B. D. Naumann and E. V. Sargent, Occup. Med. 12 (1), 33–42 (1996).

6. G. L. Fourman and M. V. Mullen, Pharm. Technol., 17 (4), 54–60 (1993).

7. R. J. Forsyth, A. LeBlanc, and M. Voaden, Pharm. Technol., 31 (1), 74- 83 (2007).

8. FDA, "Guide to Inspection of Validation of Cleaning Processes" (Rockville, MD, July 1993).

9. Health Canada, "Cleaning Validation Guidelines" (June 2002).

10. PIC/S, Recommendation on Validation Master Plan, Installation and Operational Qualification, Non-sterile Process Validation, Cleaning Validation (PI 006-2, July 2004).

11. EudraLex, "Qualification and Validation" (Annex 15, July 2001).

12. M. Lazar, Pharm. Technol., 21 (9), 56–73 (1997).

13. D. A. LeBlanc, PDA J. Pharm. Sci. and Technol., 56 (1), 31–36 (2002).

14. J.M. Cardot and E. Beyssac, Cont. Environ., 11 (6), 11–14 (2008).

15. R. J. Romanach et. al., Pharm. Technol., 23 (1), 46–58 (1999).

16. M. C. Oliver, Eur. J. Parent. Sci., 5 (4), 97–100 (2000).

17. J. E. Martinez, Pharm. Technol., 26 (11), 62–74 (2002).

18. R. J. Forsyth and V. Van Nostrand, Pharm. Technol., 28 (10), 58–72 (2004).

19. R. J. Forsyth and V. Van Nostrand, Pharm. Technol., 29 (10), 152– 161 (2005).

20. R.J. Forsyth et al., Pharm. Technol., 30 (11), 90–100 (2006).

21. R.J. Forsyth, Pharm. Technol., 33 (3), 102–111 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here